top of page
by combining tolremo’s add-on compounds with existing cancer drugs and a proprietary screening platform, the company aims to ensure that the right patient is treated with the right drug at the right time.
treating patients with the right drug at the right time
there is an unmet need for durable therapeutic treatments for cancer patients, as current drugs often lose their effectiveness over time. drug resistance therefore remains a major limiting factor to patient survival. basel-based tolremo is developing a new wave of novel resistance-breaking therapies by targeting the resistance-causing molecular mechanisms right from the start.
targeting resistance-causing molecular mechanisms
rac III
biotech
2018
2017
fund
sector
invested in
founded
bottom of page